Publications

The opinions and conclusions expressed in the following publications are those of the individual authors and do not necessarily reflect the views and opinions of Biocartis and/or its employees.

Article Highlights

Idylla assay and next generation sequencing: an integrated EGFR mutational testing algorithm

De Luca et al. Journal of Clinical Pathology 2018;71:745-750.

The Idylla^TM EGFR Mutation Test was compared to retrospective NGS results obtained with the Ion Torrent NGS system showing 100% concordance for the samples that had a valid NGS result. In addition the Idylla^TM EGFR Mutation Test was able to rescue 80% of the EGFR samples whose assessment was unsuccessful with NGS, identifying several actionable EGFR mutations.

Evaluation of a fast and fully automated platform to diagnose EGFR and KRAS mutations in formalin-fixed and paraffin-embedded non-small cell lung cancer samples in less than one day

Lambros et al. - J Clin Pathol. - June 2017

Poster Highlights

Feasibility study of a ctEGFR Prototype Assay on the fully automated Idylla platform

Reijans et al.; ESMO Poster 2019

Feasibility study comparing Idylla™ ctEGFR Mutation Assay* to NGS. The Idylla™ ctEGFR Mutation Assay* shows high concordance and ease of use combined with fast turnaround time for the testing of 49 relevant EGFR mutations in 2 ml of NSCLC plasma samples.

*Prototype

Detection of microsatellite instability (MSI) with a novel set of 7 Idylla biomarkers on colorectal cancer samples in a multi-center study

De Craene et al. Annals of Oncology 2018, 29 (suppl_8): viii14-viii57.

Comparison of the Idylla^TM MSI Test prototype to the Promega MSI analysis system as well as IHC staining. Concordance analysis showed an overall agreement of 98.7% and 97.6% with Promega and IHC, respectively. Furthermore, analysis revealed a higher number of invalid results for Promega (3.8%) and IHC (13.2%) compared to the prototype Idylla^TM MSI Test (2.2%).

Presentation Highlights

Implementation and Cost Benefit Analysis of the fully automated Idyllasystem in a large laboratory setting

Yi Ding M.D., Ph.D. - Geisinger

presented at Biocartis Corporate Workshop, AMP 2019

Empowering STAT DNA Testing for Molecular Oncology Applications

Gregory J. Tsongalis, BS, MS, PhD. - Dartmouth Hitchcock Medical Center

presented at Biocartis Corporate Workshop, AMP 2017